Product Overview
CDFI is a potent, selective inhibitor of the lipid II flippase MurJ, an essential enzyme in bacterial cell wall biosynthesis. MurJ is responsible for flipping the lipid II precursor across the cytoplasmic membrane, a critical step in peptidoglycan synthesis. By inhibiting MurJ, CDFI disrupts bacterial cell wall formation, exhibiting bactericidal activity against Gram-positive pathogens including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).
Chemically, CDFI is 2-(2-chlorophenyl)-3-(1-(2,3-dimethylbenzyl)piperidin-4-yl)-5-fluoro-1H-indole with the molecular formula C₂₈H₂₈ClFN₂ and a molecular weight of 446.99 g/mol. It is a white to pale yellow crystalline powder with solubility in DMSO and DMF, and limited aqueous solubility. The compound is stable under proper storage conditions and is supplied at ≥98% purity as determined by HPLC analysis.
Mechanism of Action
CDFI exerts its antibacterial effects through a novel mechanism targeting the MurJ flippase:
• MurJ Inhibition: Selectively binds to MurJ, blocking the translocation of lipid II from the cytoplasmic to the periplasmic side of the bacterial membrane
• Cell Wall Disruption: Prevents peptidoglycan precursor delivery, leading to impaired cell wall synthesis and bacterial cell lysis
• Broad-spectrum Activity: Demonstrates activity against multiple Gram-positive pathogens including MRSA, VRE, and Streptococcus species
• Synergistic Effects: Enhances the activity of β-lactam antibiotics against resistant strains when used in combination
Research Applications & Market Significance
CDFI represents a promising lead compound in the development of new antibacterial agents targeting resistant pathogens:
• Antibiotic Resistance Research: Valuable tool for studying novel antibacterial targets and overcoming multidrug resistance
• Cell Wall Biology: Useful probe for investigating peptidoglycan synthesis and bacterial membrane biology
• Drug Development: Serves as a lead compound for the development of next-generation antibacterial agents
• Combinatorial Therapy Research: Enables studies of synergistic effects with existing antibiotic classes
The growing threat of antibiotic resistance has driven increased investment in novel antibacterial targets, making MurJ inhibitors like CDFI valuable research tools for both academic and pharmaceutical research institutions.
Quality Specifications
Our CDFI is manufactured under strict quality control conditions:
• Purity: ≥98.0% determined by HPLC
• Identity confirmed by NMR and mass spectrometry
• Water content: ≤1.0%
• Residual solvents: Meet ICH Q3C guidelines
• Each batch accompanied by comprehensive Certificate of Analysis (COA)
• Stable for 24 months when stored at 8-10°C in sealed containers protected from light
Packaging & Shipping
We offer flexible packaging options to meet diverse customer needs:
• Research quantities: 10mg, 50mg, 100mg amber glass vials
• Bulk quantities: 1g, 5g amber glass bottles
• Custom packaging available upon request
• Shipped at ambient temperature for routine orders
• International shipping available with proper documentation
• Cold chain shipping available upon request for temperature-sensitive orders
